CA2126819A1 - Trousse et methode de preciblage - Google Patents

Trousse et methode de preciblage

Info

Publication number
CA2126819A1
CA2126819A1 CA002126819A CA2126819A CA2126819A1 CA 2126819 A1 CA2126819 A1 CA 2126819A1 CA 002126819 A CA002126819 A CA 002126819A CA 2126819 A CA2126819 A CA 2126819A CA 2126819 A1 CA2126819 A1 CA 2126819A1
Authority
CA
Canada
Prior art keywords
antibody
ligand
effector moiety
epitope
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002126819A
Other languages
English (en)
Inventor
Richard P. Mccabe
Ebo S. Bos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of CA2126819A1 publication Critical patent/CA2126819A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA002126819A 1993-07-09 1994-06-27 Trousse et methode de preciblage Abandoned CA2126819A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93202016.7 1993-07-09
EP93202016 1993-07-09

Publications (1)

Publication Number Publication Date
CA2126819A1 true CA2126819A1 (fr) 1995-01-10

Family

ID=8213969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002126819A Abandoned CA2126819A1 (fr) 1993-07-09 1994-06-27 Trousse et methode de preciblage

Country Status (6)

Country Link
JP (1) JPH07181186A (fr)
KR (1) KR960014510A (fr)
AU (1) AU678474B2 (fr)
CA (1) CA2126819A1 (fr)
FI (1) FI943269A (fr)
ZA (1) ZA944893B (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013805A1 (fr) * 1992-12-10 1994-06-23 Celltech Limited Anticorps humanises diriges contre l'antigene a33

Also Published As

Publication number Publication date
ZA944893B (en) 1995-02-20
KR960014510A (ko) 1996-05-22
FI943269A (fi) 1995-01-10
AU678474B2 (en) 1997-05-29
JPH07181186A (ja) 1995-07-21
AU6736094A (en) 1995-01-19
FI943269A0 (fi) 1994-07-08

Similar Documents

Publication Publication Date Title
JP3904238B2 (ja) グリコシル化されたヒト化ｂ細胞特異的抗体
Pastan et al. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas
US5443953A (en) Preparation and use of immunoconjugates
CA2195556C (fr) Immunoconjugues polyspecifiques et composites d'anticorps permettant le ciblage du phenotype multipharmacoresistant
US4863713A (en) Method and system for administering therapeutic and diagnostic agents
KR0183980B1 (ko) 이중특이성 및 올리고특이성 일가 및 올리고가 수용체 및 이를 포함하는 약제학적 조성물
JP3683270B2 (ja) 受容体Ｔｉｅを認識するモノクローナル抗体およびそれらの用途
US5534254A (en) Biosynthetic binding proteins for immuno-targeting
Karacay et al. Experimental pretargeting studies of cancer with a humanized anti-CEA× murine anti-[In-DTPA] bispecific antibody construct and a 99mTc-/188Re-labeled peptide
US20180155449A1 (en) Covalent disulfide-linked diabodies and uses thereof
US5034223A (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
WO1991013974A1 (fr) Anticorps monoclonal et immunoconjugues de traitement et de detection de troubles des lymphocytes b
EP0385601A2 (fr) Anticorps réticulés et leurs procédés de préparation
Sharifi et al. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
WO1994015644A1 (fr) Composes de ciblage
US6509451B1 (en) Cross-linked antibodies and processes for their preparation
US6008319A (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA1340312C (fr) Methodes pour ameliorer le ciblage d'anticorps, de fragments d'anticorpsd'hormones et d'autres agents, ainsi que leurs conjugues
US5407805A (en) Monoclonal antibody reactive to various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
CA2232601A1 (fr) Proteines recombinees ayant de multiples liaisons disulfure et conjugues a substitution thiol de ces proteines
CA2389386A1 (fr) Anticorps se liant a un enantiomere non naturel (l-biotine) et leur utilisation en tant qu'agents de ciblage
EP0650735A2 (fr) Kit et méthode de préciblage
AU678474B2 (en) Kit and method for pretargeting
WO1996000087A2 (fr) Materiel de preciblage et nouveaux conjugues de preciblage

Legal Events

Date Code Title Description
FZDE Dead